Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
about
Illegal drugs laws: clearing a 50-year-old obstacle to researchHow Drug Control Policy and Practice Undermine Access to Controlled Medicines.Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs.The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.Monoamine reuptake inhibitors in Parkinson's disease.Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian ratsThe serotonergic system in motor and non-motor manifestations of Parkinson's disease.Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.A convenient biomimetic synthesis of optically active putative neurotoxic metabolites of MDMA ("ecstasy") from R-(-)- and S-(+)-N-methyl-α-methyldopamine precursors.Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.MDMA modulates spontaneous firing of subthalamic nucleus neurons in vitro.Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.(±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.Effects of Schedule I drug laws on neuroscience research and treatment innovation.Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
P2860
Q28543098-A1C8C9A7-A1D2-419C-8F8D-219E124E99FDQ33805755-264C1ECE-A21B-4187-90DE-E7847D5AD3C0Q34419823-9CD7CD37-4342-47D1-9139-17798B55122CQ34429523-760942A5-29DA-44C4-AA59-B77DF193B3B6Q35165280-2020C348-46D3-448F-B2DB-DB5852C8ACC1Q36243814-FFD5C866-7063-47A0-AC13-65384C1D46F9Q38118061-B9199C00-1A6A-47EF-8F51-4A3EB27DA2F0Q38837020-52BF0EFC-829D-45E0-803C-CCAC213286DCQ39125374-C82E43DC-0FB3-4406-AE68-088C63D30EECQ39635524-4ADBE8CE-F356-48D0-AD94-B3CAFB8255D1Q40790760-1B36D9D6-9958-4509-A56C-C042BEDCEBE1Q42465875-A367BABF-BED4-4AB6-95E0-7CBB46780074Q47662199-E68CE6A9-053C-45B5-BD52-54D82DCE6B87Q47777762-4996DE6A-D80F-40FF-9B31-0F202D8E585DQ48300577-B6984AE2-A654-4F2D-820A-72278A7ACE13Q48463442-76D694E3-8845-4DFE-BC19-0DEA2BE2D784Q49788107-77C8F7C9-983B-4BC3-8436-0AFE07EA52AAQ53542537-81B0DF90-8097-473D-8D54-E8E729CAEEE5
P2860
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@ast
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@en
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@nl
type
label
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@ast
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@en
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@nl
prefLabel
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@ast
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@en
Characterization of 3,4-methyl ...... A extends duration of ON-time.
@nl
P2093
P50
P1476
Characterization of 3,4-methyl ...... MA extends duration of ON-time
@en
P2093
James B Koprich
Katie D Lewis
M Gabriela Reyes
Philippe Huot
Susan H Fox
P304
P356
10.1523/JNEUROSCI.1171-11.2011
P407
P577
2011-05-01T00:00:00Z